speb/financial-data huggingface dataset:
Financial ratios for PHARM.AS — annual report dated 2024-12-31
Total revenue: 309583333.3333334
Gross profit: 272709375
Operating income: -3817708.3333333335
Net income: -12334375
Capital expenditures: 829166.6666666667
Operating cash flow: -1869791.6666666667
Depreciation & amortization: 16739583.333333334
Net tangible assets: 166689583.33333334
Owner earnings: 3576041.666666667
Buffett classification: The Gruesome
Stock price: 0.9687500000000001
Shares outstanding: 706252300
Book value: 230271875
P/B ratio: 2.9711918384518308
Market cap (USD): 684181915.6250001
Debt to equity: 0.5080633852194644
Current ratio: 3.7727974851630033
Quick ratio: 3.0177501964716402
Interest coverage ratio: -0.4194803708366716
COGS to revenue (%): 11.910834454912516
R&D to revenue (%): 27.976783310901748
SG&A to revenue (%): 33.383580080753696
Free cash flow (dilution-adjusted): -14415625.000000002
Buyback yield (%): 0
Retained earnings: -286967708.3333334
Inventory turnover: 0.6352559040987725
Receivables turnover: 5.923622737782031
Capitalized R&D asset: 156355836.82033098
ROCI (R&D-adjusted, %): 1.9695543577989565
Rosenberg metric: 0.36762395884725896
FCF margin (%): -4.656460296096904
Revenue growth (%): 13.577997358509048
Rule of 40 score: 8.921537062412144
Financial ratios for PHARM.AS — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.9687500000000001
Shares outstanding: 706252300
Market cap (USD): 684181915.6250001
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for PHARM.AS — quarterly report dated 2025-03-31
Total revenue: 85971739.13043478
Gross profit: 76925000
Operating income: -8072826.0869565215
Net income: -15998913.04347826
Capital expenditures: 313043.47826086957
Operating cash flow: 252173.91304347824
Depreciation & amortization: 2806521.7391304346
Net tangible assets: 81668478.26086956
Owner earnings: -13505434.782608693
Return on net tangible assets (%): -16.536900246223464
Buffett classification: The Gruesome
Stock price: 0.8478260869565217
Shares outstanding: 706252300
Book value: 234010869.56521738
P/B ratio: 2.5587662873333645
Market cap (USD): 598779123.9130435
Debt to equity: 0.5534070323749362
Current ratio: 2.761375361122575
Quick ratio: 1.9959760627321501
Interest coverage ratio: -1.4568458218909377
COGS to revenue (%): 10.522922092699824
R&D to revenue (%): 26.730219738538953
SG&A to revenue (%): 72.13695096973221
Free cash flow (dilution-adjusted): -2860869.565217391
Buyback yield (%): 0
Retained earnings: -318261956.5217391
Inventory turnover: 0.14024534088228355
Receivables turnover: 1.6655926885252805
Capitalized R&D asset: 22980434.782608695
ROCI (R&D-adjusted, %): 1.9226979865642793
FCF margin (%): -3.327686044453435
Rule of 40 score: -3.327686044453435
Financial ratios for PHARM.AS — quarterly report dated 2025-06-30
Total revenue: 109671764.70588236
Gross profit: 99116470.5882353
Operating income: 10588235.294117648
Net income: 5522352.94117647
Capital expenditures: 150588.23529411765
Operating cash flow: 13815294.11764706
Depreciation & amortization: 3178823.529411765
Net tangible assets: 121941176.47058824
Owner earnings: 8550588.235294117
Return on net tangible assets (%): 7.012059816690785
Capex to operating income (%): 1.422222222222222
Buffett classification: The Great
Stock price: 1.0705882352941176
P/E ratio: 34.229313645078825
Shares outstanding: 706252300
Book value: 281824705.88235295
P/B ratio: 2.6828925489770445
Market cap (USD): 756105403.5294118
Debt to equity: 0.5356938605975347
Current ratio: 2.7947510859430076
Quick ratio: 2.0702394760182847
Effective tax rate (%): 35.7253849413759
Interest coverage ratio: 2250
COGS to revenue (%): 9.624440844874009
R&D to revenue (%): 25.41809248988962
SG&A to revenue (%): 55.30298966970961
Free cash flow (dilution-adjusted): 9575294.11764706
Buyback yield (%): 0
Retained earnings: -336507058.8235294
Inventory turnover: 0.14081456485913835
Receivables turnover: 1.7481013370337728
Capitalized R&D asset: 43273361.892583124
ROCI (R&D-adjusted, %): 4.62808737248588
Rosenberg metric: 0.9656680040287806
FCF margin (%): 8.7308653629547
Revenue growth (%): 27.567228271944483
Rule of 40 score: 36.29809363489918
Financial ratios for PHARM.AS — quarterly report dated 2025-09-30
Total revenue: 114455294.11764707
Gross profit: 106136470.5882353
Operating income: 18530588.23529412
Net income: 8880000
Capital expenditures: 82352.94117647059
Operating cash flow: 37677647.05882353
Depreciation & amortization: 6923529.4117647065
Net tangible assets: 152609411.7647059
Owner earnings: 15721176.470588237
Return on net tangible assets (%): 10.301577267611279
Capex to operating income (%): 0.44441622754110843
Buffett classification: The Great
Stock price: 1.4588235294117646
P/E ratio: 29.006122549019604
Shares outstanding: 706252300
Book value: 311345882.35294116
P/B ratio: 3.309173274285455
Market cap (USD): 1030297472.9411764
Debt to equity: 0.49470987439730363
Current ratio: 3.157631321518757
Quick ratio: 2.3939759310235003
Effective tax rate (%): 40.82928358676908
Interest coverage ratio: 1.9822552227535866
COGS to revenue (%): 7.268185883005951
R&D to revenue (%): 24.036099376072855
SG&A to revenue (%): 52.50547349594499
Free cash flow (dilution-adjusted): 33825882.35294118
Buyback yield (%): 0
Retained earnings: -325738823.5294118
Inventory turnover: 0.10532352240228789
Receivables turnover: 2.231046186304637
Capitalized R&D asset: 53771367.00767263
ROCI (R&D-adjusted, %): 3.9230288159789017
Rosenberg metric: 0.25182527959485124
FCF margin (%): 29.55379444324524
Revenue growth (%): 4.36167816264576
Rule of 40 score: 33.915472605891004
Financial ratios for PHARM.AS — quarterly report dated 2025-12-31
Total revenue: 125294117.64705883
Gross profit: 100470588.23529412
Operating income: 2352941.1764705884
Net income: 6235294.117647059
Capital expenditures: 316470.5882352941
Operating cash flow: 12596470.588235294
Depreciation & amortization: 3771764.7058823532
Net tangible assets: 166545882.3529412
Owner earnings: 9690588.235294119
Return on net tangible assets (%): 5.818569692859767
Capex to operating income (%): 13.449999999999998
Buffett classification: The Great
Stock price: 1.6823529411764706
P/E ratio: 256.14006541162064
Shares outstanding: 706252300
Book value: 326002352.9411764
P/B ratio: 3.644653553565114
Market cap (USD): 1188165634.1176472
Debt to equity: 0.41780643950603036
Current ratio: 2.5862890898256343
Quick ratio: 2.025779205637744
Effective tax rate (%): -10.416666666666668
Interest coverage ratio: 1.4285714285714286
COGS to revenue (%): 19.812206572769952
R&D to revenue (%): 30.140845070422532
SG&A to revenue (%): 48.16901408450705
Free cash flow (dilution-adjusted): 6974117.647058823
Buyback yield (%): 0
Retained earnings: -321156470.5882353
Inventory turnover: 0.32510554374287387
Receivables turnover: 2.1985508143927666
Capitalized R&D asset: 65396035.294117644
ROCI (R&D-adjusted, %): 1.7525523035215924
Rosenberg metric: -0.20595278823126956
FCF margin (%): 5.566197183098591
Revenue growth (%): 9.46991889975022
Rule of 40 score: 15.036116082848812
Financial ratios for PHARM.AS — annual report dated 2025-12-31
Total revenue: 442510588.2352941
Gross profit: 388981176.47058827
Operating income: 24565882.352941178
Net income: 3354117.6470588236
Capital expenditures: 888235.2941176471
Operating cash flow: 64362352.941176474
Depreciation & amortization: 13195294.11764706
Net tangible assets: 166545882.3529412
Owner earnings: 15661176.470588237
Return on net tangible assets (%): 9.403520669096665
Capex to operating income (%): 3.6157272161294953
Buffett classification: The Great
Stock price: 1.6823529411764706
P/E ratio: 354.24089407225534
Shares outstanding: 706252300
Book value: 326002352.9411764
P/B ratio: 3.644653553565114
Market cap (USD): 1188165634.1176472
Debt to equity: 0.41780643950603036
Current ratio: 2.5862890898256343
Quick ratio: 2.025779205637744
Effective tax rate (%): 80.25219895695493
Interest coverage ratio: 1.9480361974064744
COGS to revenue (%): 12.096752753008237
R&D to revenue (%): 26.68384139694896
SG&A to revenue (%): 31.221585924165325
Free cash flow (dilution-adjusted): 47278823.52941176
Buyback yield (%): 0
Retained earnings: -321156470.5882353
Inventory turnover: 0.7010569782133061
Receivables turnover: 7.764786028364402
Capitalized R&D asset: 201376967.27941176
ROCI (R&D-adjusted, %): 7.48317980590177
Rosenberg metric: 1.3424528775754354
FCF margin (%): 10.68422423923389
Revenue growth (%): 42.937471300767925
Rule of 40 score: 53.62169554000182
Financial ratios for PREVA.AS — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 5.215909090909091
Shares outstanding: 9933760
Market cap (USD): 51813589.09090909
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for PREVA.AS — annual report dated 2022-12-31
Total revenue: 4418085.106382979
Gross profit: 3415957.446808511
Operating income: -2869148.936170213
Net income: -2692553.1914893617
Capital expenditures: 0
Operating cash flow: 4490425.531914894
Depreciation & amortization: 106382.97872340426
Net tangible assets: 97761702.12765957
Owner earnings: -2586170.212765957
Return on net tangible assets (%): -2.645381735875337
Buffett classification: The Gruesome
Stock price: 4.23404255319149
Shares outstanding: 9933760
Book value: 97761702.12765957
P/B ratio: 0.43022944197788804
Market cap (USD): 42059962.55319149
Debt to equity: 0.07881735875337338
Current ratio: 4.151217739003998
Quick ratio: 4.151217739003998
Interest coverage ratio: -9.879120879120878
COGS to revenue (%): 22.68239826631351
SG&A to revenue (%): 20.105947507825668
Free cash flow (dilution-adjusted): 4490425.531914894
Buyback yield (%): 0
Retained earnings: -2692553.1914893617
Receivables turnover: 42.37755102040816
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.925956061838894
FCF margin (%): 101.63737057548758
Rule of 40 score: 101.63737057548758
Financial ratios for PREVA.AS — annual report dated 2023-12-31
Total revenue: 3650000
Gross profit: 2552222.222222222
Operating income: 7008888.888888889
Net income: 6466666.666666666
Capital expenditures: 0
Operating cash flow: -1428888.8888888888
Depreciation & amortization: 135555.55555555556
Net tangible assets: 108024444.44444445
Owner earnings: 6602222.222222222
Return on net tangible assets (%): 6.111785398366624
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 4.488888888888889
P/E ratio: 6.895599725085912
Shares outstanding: 9933760
Book value: 108024444.44444445
P/B ratio: 0.4127912447799881
Market cap (USD): 44591544.88888889
Debt to equity: 0.10175680401555202
Current ratio: 3.0006171751013926
Quick ratio: 3.0006171751013926
Effective tax rate (%): 0
Interest coverage ratio: 11.224199288256228
COGS to revenue (%): 30.076103500761036
SG&A to revenue (%): 15.403348554033485
Free cash flow (dilution-adjusted): -1428888.8888888888
Buyback yield (%): 0
Retained earnings: 6466666.666666666
Receivables turnover: 9.439655172413792
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.4781818368541595
FCF margin (%): -39.147640791476405
Revenue growth (%): -17.385022875030106
Rule of 40 score: -56.53266366650651
Financial ratios for PREVA.AS — annual report dated 2024-12-31
Total revenue: 5607291.666666667
Gross profit: 4461458.333333334
Operating income: 7689583.333333334
Net income: 7433333.333333334
Capital expenditures: 0
Operating cash flow: 6633333.333333334
Depreciation & amortization: 133333.33333333334
Net tangible assets: 107296875
Owner earnings: 7566666.666666667
Return on net tangible assets (%): 7.052084850249988
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 4.583333333333334
P/E ratio: 6.125076233183857
Shares outstanding: 9933760
Book value: 107296875
P/B ratio: 0.42433419736905986
Market cap (USD): 45529733.333333336
Debt to equity: 0.05165768652007185
Current ratio: 5.1038533161438195
Quick ratio: 5.1038533161438195
Effective tax rate (%): 0
Interest coverage ratio: 18.363184079601993
COGS to revenue (%): 20.434701839123168
SG&A to revenue (%): 10.663198959687907
Free cash flow (dilution-adjusted): 6633333.333333334
Buyback yield (%): 0
Retained earnings: 7433333.333333334
Receivables turnover: 26.387254901960787
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.164555733488622
FCF margin (%): 118.2983466468512
Revenue growth (%): 53.62442922374429
Rule of 40 score: 171.9227758705955
Financial ratios for PREVA.AS — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 107296875
Buffett classification: The Gruesome
Stock price: 4.583333333333334
Shares outstanding: 9933760
Book value: 107296875
P/B ratio: 0.42433419736905986
Market cap (USD): 45529733.333333336
Debt to equity: 0.05165768652007185
Current ratio: 5.1038533161438195
Quick ratio: 5.1038533161438195
Buyback yield (%): 0
Retained earnings: 7433333.333333334
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for PREVA.AS — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 128102352.94117647
Buffett classification: The Gruesome
Stock price: 5.341176470588236
Shares outstanding: 9933760
Book value: 128102352.94117647
P/B ratio: 0.4141841578884532
Market cap (USD): 53057965.17647059
Debt to equity: 0.05126415458227337
Current ratio: 0.9255988386160174
Quick ratio: 0.9255988386160174
Buyback yield (%): 0
Retained earnings: 7456470.588235294
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RDI — annual report dated 2021-12-31
Capital expenditures: 145165000
Buffett classification: The Gruesome
Stock price: 4.04
Shares outstanding: 21036670
Market cap (USD): 84988146.8
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RDI — annual report dated 2022-12-31
Total revenue: 203115000
Gross profit: 15400000
Operating income: -26934000
Net income: -36184000
Capital expenditures: 0
Operating cash flow: -26351000
Depreciation & amortization: 22562000
Net tangible assets: 34961000
Owner earnings: -13622000
Return on net tangible assets (%): -38.963416378250045
Buffett classification: The Gruesome
Stock price: 2.77
Shares outstanding: 21036670
Book value: 63279000
P/B ratio: 0.920867521610645
Market cap (USD): 58271575.9
Debt to equity: 7.010398394412048
Current ratio: 0.3905181483429774
Quick ratio: 0.37723566543924253
Interest coverage ratio: -1.8714563646470261
COGS to revenue (%): 92.41808827511508
SG&A to revenue (%): 10.543780616891908
Free cash flow (dilution-adjusted): -28239000
Buyback yield (%): 0
Retained earnings: -48816000
Inventory turnover: 116.16027227722772
Receivables turnover: 32.68667524943675
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -5.7873916771059175
FCF margin (%): -13.902961376560077
Rule of 40 score: -13.902961376560077
Financial ratios for RDI — annual report dated 2023-12-31
Total revenue: 222744000
Gross profit: 26563000
Operating income: -12031000
Net income: -30673000
Capital expenditures: 1774000
Operating cash flow: -9735000
Depreciation & amortization: 20118000
Net tangible assets: 5514000
Owner earnings: -12329000
Return on net tangible assets (%): -223.59448676097207
Buffett classification: The Gruesome
Stock price: 1.91
Shares outstanding: 21036670
Book value: 32996000
P/B ratio: 1.2177245635834646
Market cap (USD): 40180039.699999996
Debt to equity: 12.691750515213965
Current ratio: 0.3046040776500397
Quick ratio: 0.29163617478340925
Interest coverage ratio: -0.6195797713461737
COGS to revenue (%): 88.07465072010918
SG&A to revenue (%): 9.056136192220666
Free cash flow (dilution-adjusted): -11598000
Buyback yield (%): 0
Retained earnings: -79489000
Inventory turnover: 119.04186893203884
Receivables turnover: 29.45959529162809
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.9635340716509675
FCF margin (%): -5.206874259239306
Revenue growth (%): 9.663983457647147
Rule of 40 score: 4.457109198407841
Financial ratios for RDI — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.63
Shares outstanding: 21036670
Market cap (USD): 34289772.099999994
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RDI — annual report dated 2024-12-31
Total revenue: 210527000
Gross profit: 21907000
Operating income: -14033000
Net income: -35301000
Capital expenditures: 0
Operating cash flow: -3833000
Depreciation & amortization: 17161000
Net tangible assets: -29876000
Owner earnings: -18140000
Buffett classification: The Gruesome
Stock price: 1.32
Shares outstanding: 21036670
Book value: -4790000
Market cap (USD): 27768404.400000002
Debt to equity: -81.46513569937369
Current ratio: 0.3529258906364075
Quick ratio: 0.3425005877767191
Interest coverage ratio: -0.6633733572846743
COGS to revenue (%): 89.59420881882134
SG&A to revenue (%): 9.576443876557402
Free cash flow (dilution-adjusted): -6189000
Buyback yield (%): 0
Retained earnings: -114790000
Inventory turnover: 111.9406528189911
Receivables turnover: 39.90276724791509
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4.535772581088288
FCF margin (%): -2.9397654457623013
Revenue growth (%): -5.484771755917107
Rule of 40 score: -8.424537201679408
Financial ratios for RDI — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.32
Shares outstanding: 21036670
Market cap (USD): 27768404.400000002
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RDI — quarterly report dated 2025-03-31
Total revenue: 40169000
Gross profit: 1637000
Operating income: -6891000
Net income: -4752000
Capital expenditures: 0
Operating cash flow: -7702000
Depreciation & amortization: 3689000
Net tangible assets: -33701000
Owner earnings: -1063000
Buffett classification: The Gruesome
Stock price: 1.39
Shares outstanding: 21036670
Book value: -8680000
Market cap (USD): 29240971.299999997
Debt to equity: -42.33041474654378
Current ratio: 0.2336486810382506
Quick ratio: 0.2234903492323093
Interest coverage ratio: -1.4531843104175453
COGS to revenue (%): 95.92471806617043
SG&A to revenue (%): 12.828300430680375
Free cash flow (dilution-adjusted): -8302000
Buyback yield (%): 0
Retained earnings: -119542000
Inventory turnover: 26.73976405274115
Receivables turnover: 28.61039886039886
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.30379619878642
FCF margin (%): -20.66767905598845
Rule of 40 score: -20.66767905598845
Financial ratios for RDI — quarterly report dated 2025-06-30
Total revenue: 60378000
Gross profit: 11655000
Operating income: 2891000
Net income: -2667000
Capital expenditures: 0
Operating cash flow: 1551000
Depreciation & amortization: 3651000
Net tangible assets: -34295000
Owner earnings: 984000
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 1.34
Shares outstanding: 21036670
Book value: -8428000
Market cap (USD): 28189137.8
Debt to equity: -42.67619838633128
Current ratio: 0.16305739319744578
Quick ratio: 0.15139017715464043
Interest coverage ratio: 0.6639871382636656
COGS to revenue (%): 80.69661134850442
SG&A to revenue (%): 8.917155255225413
Free cash flow (dilution-adjusted): 1021000
Buyback yield (%): 0
Retained earnings: -122213000
Inventory turnover: 32.01248357424441
Receivables turnover: 17.9110056363097
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.9397836319662966
FCF margin (%): 1.6910132829838682
Revenue growth (%): 50.30994050138167
Rule of 40 score: 52.000953784365535
Financial ratios for RDI — quarterly report dated 2025-09-30
Total revenue: 52170000
Gross profit: 7565000
Operating income: -329000
Net income: -4157000
Capital expenditures: 0
Operating cash flow: 295000
Depreciation & amortization: 3543000
Net tangible assets: -38348000
Owner earnings: -614000
Buffett classification: The Gruesome
Stock price: 1.47
Shares outstanding: 21036670
Book value: -13012000
Market cap (USD): 30923904.9
Debt to equity: -27.612434675683986
Current ratio: 0.1686937179349191
Quick ratio: 0.15384960355899974
Interest coverage ratio: -0.07882127455678006
COGS to revenue (%): 85.4993291163504
SG&A to revenue (%): 8.928502971056162
Free cash flow (dilution-adjusted): -96000
Buyback yield (%): 0
Retained earnings: -126370000
Inventory turnover: 26.951661631419938
Receivables turnover: 18.78646020885848
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.10163920245664115
FCF margin (%): -0.18401380103507764
Revenue growth (%): -13.594355559972177
Rule of 40 score: -13.778369361007256
Financial ratios for RDI — annual report dated 2025-12-31
Total revenue: 202988000
Gross profit: 27197000
Operating income: -5307000
Net income: -14140000
Capital expenditures: 0
Operating cash flow: -1578000
Depreciation & amortization: 14312000
Net tangible assets: -44418000
Owner earnings: 172000
Buffett classification: The Gruesome
Stock price: 1.05
Shares outstanding: 21036670
Book value: -18098000
Market cap (USD): 22088503.5
Debt to equity: -19.945076804066748
Current ratio: 0.16966736920695905
Quick ratio: 0.1567261103895599
Interest coverage ratio: -0.2959843837144451
COGS to revenue (%): 86.60167103474097
SG&A to revenue (%): 9.510907048692534
Free cash flow (dilution-adjusted): -3492000
Buyback yield (%): 0
Retained earnings: -128930000
Inventory turnover: 105.6436298076923
Receivables turnover: 44.583351636283766
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.7323436092287203
FCF margin (%): -1.7202987368711449
Revenue growth (%): -3.5810133617065745
Rule of 40 score: -5.30131209857772
Financial ratios for RDI — quarterly report dated 2025-12-31
Total revenue: 50272000
Gross profit: 6342000
Operating income: -976000
Net income: -2560000
Capital expenditures: 0
Operating cash flow: 4278000
Depreciation & amortization: 3429000
Net tangible assets: -44418000
Owner earnings: 869000
Buffett classification: The Gruesome
Stock price: 1.05
Shares outstanding: 21036670
Book value: -18098000
Market cap (USD): 22088503.5
Debt to equity: -19.945076804066748
Current ratio: 0.16966736920695905
Quick ratio: 0.1567261103895599
Interest coverage ratio: -0.2094420600858369
COGS to revenue (%): 87.3846276257161
SG&A to revenue (%): 8.179503500954805
Free cash flow (dilution-adjusted): 3885000
Buyback yield (%): 0
Retained earnings: -128930000
Inventory turnover: 26.400240384615383
Receivables turnover: 11.041511091587964
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.31859192813401754
FCF margin (%): 7.727959898154042
Revenue growth (%): -3.6381061912976804
Rule of 40 score: 4.089853706856362
Financial ratios for RELIABLE.NS — annual report dated 2022-03-31
Total revenue: 7040920.4800211
Gross profit: 5568099.696689964
Operating income: 952050.6395885533
Net income: 493960.17407358566
Capital expenditures: 972596.5976526442
Operating cash flow: 853395.7536595016
Depreciation & amortization: 48028.484768561255
Net tangible assets: 4981722.273506528
Owner earnings: -430607.9388104973
Return on net tangible assets (%): -8.643756419351767
Capex to operating income (%): 102.15807407817825
Buffett classification: The Gruesome
Stock price: 0.5396281155215614
P/E ratio: 11.274111648023066
Shares outstanding: 10320000
Book value: 5470895.423974681
P/B ratio: 1.017925169576096
Market cap (USD): 5568962.152182514
Debt to equity: 0.34154337146686337
Current ratio: 1.6010979150618372
Quick ratio: 1.6000313206301375
Effective tax rate (%): 29.0331748166954
Interest coverage ratio: 3.6500328631376715
COGS to revenue (%): 20.91801473273736
SG&A to revenue (%): 1.8901955936641364
Free cash flow (dilution-adjusted): -119200.84399314255
Buyback yield (%): 0
Retained earnings: 2217341.4216009495
Inventory turnover: 443.1904761904762
Receivables turnover: 2.058340722464243
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 13.833474809294874
FCF margin (%): -1.6929724505677892
Rule of 40 score: -1.6929724505677892
Financial ratios for RELIABLE.NS — annual report dated 2023-03-31
Total revenue: 8870475.03045067
Gross profit: 7538745.432399513
Operating income: 884141.2911084044
Net income: 580596.8331303289
Capital expenditures: 446175.39585870894
Operating cash flow: -1880718.635809988
Depreciation & amortization: 257381.24238733255
Net tangible assets: 4407442.143727162
Owner earnings: 391802.67965895246
Return on net tangible assets (%): 8.889570569101647
Capex to operating income (%): 50.464264065685796
Buffett classification: The Good
Stock price: 0.6571254567600489
P/E ratio: 11.680281956070239
Shares outstanding: 10320000
Book value: 6590937.880633374
P/B ratio: 1.028918013882421
Market cap (USD): 6781534.7137637045
Debt to equity: 0.5378495553633602
Current ratio: 1.2761812105429753
Quick ratio: 1.2760239164671363
Effective tax rate (%): 21.069364640426553
Interest coverage ratio: 3.1848016848016845
COGS to revenue (%): 15.013058415469075
SG&A to revenue (%): 1.1936572625936128
Free cash flow (dilution-adjusted): -3342484.7746650428
Buyback yield (%): 0
Retained earnings: 1915542.0219244824
Inventory turnover: 1349.814814814815
Receivables turnover: 2.11916533054761
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.51742576299693
FCF margin (%): -37.6810121576457
Revenue growth (%): 25.984593287497088
Rule of 40 score: -11.696418870148609
Financial ratios for RELIABLE.NS — annual report dated 2024-03-31
Total revenue: 9519007.075188871
Gross profit: 7789183.355318383
Operating income: 1161182.39597074
Net income: 634500.5396330495
Capital expenditures: 231070.87180717112
Operating cash flow: -34728.38469840508
Depreciation & amortization: 408718.0717112364
Net tangible assets: 5890310.588799616
Owner earnings: 812147.7395371147
Return on net tangible assets (%): 13.787859354673213
Capex to operating income (%): 19.899618923691794
Buffett classification: The Great
Stock price: 0.7857485604606526
P/E ratio: 12.78001299832395
Shares outstanding: 10320000
Book value: 7133840.988128073
P/B ratio: 1.136684313183959
Market cap (USD): 8108925.143953934
Debt to equity: 0.6407829333440916
Current ratio: 1.5872389615721183
Quick ratio: 1.5870639456370257
Effective tax rate (%): 23.107888159042027
Interest coverage ratio: 3.4332364203659056
COGS to revenue (%): 18.172312576374104
SG&A to revenue (%): 0.9608334698093955
Free cash flow (dilution-adjusted): -265799.2565055762
Buyback yield (%): 0
Retained earnings: 2437078.786425231
Inventory turnover: 1780.8641975308642
Receivables turnover: 1.5247540347520754
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.647727272727272
FCF margin (%): -2.792300230539563
Revenue growth (%): 7.3111309429530325
Rule of 40 score: 4.51883071241347
Financial ratios for RELIABLE.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 5385427.615862398
Buffett classification: The Gruesome
Stock price: 0.960224558050645
Shares outstanding: 10320000
Book value: 7452245.58050645
P/B ratio: 1.3297357597827866
Market cap (USD): 9909517.439082656
Debt to equity: 0.6129696651076613
Current ratio: 1.1414643179706436
Quick ratio: 1.1413765992423703
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RELIABLE.NS — quarterly report dated 2024-12-31
Total revenue: 3894090.2203053967
Gross profit: 3570287.9123440958
Operating income: 640564.1683179857
Net income: 479892.76139410184
Capital expenditures: 0
Depreciation & amortization: 167595.29082643663
Owner earnings: 647488.0522205385
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.8330807786455298
P/E ratio: 4.47880981297061
Shares outstanding: 10320000
Market cap (USD): 8597393.635621868
Effective tax rate (%): 24.26695117913248
Interest coverage ratio: 5.795001581777918
COGS to revenue (%): 8.315223573220305
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RELIABLE.NS — annual report dated 2025-03-31
Total revenue: 15266097.732055178
Gross profit: 13665419.686696282
Operating income: 1537970.5400981996
Net income: 1210030.395136778
Capital expenditures: 339244.79775543604
Operating cash flow: -3253963.058218377
Depreciation & amortization: 447813.88823942014
Net tangible assets: 6677589.43184475
Owner earnings: 1318599.4856207622
Return on net tangible assets (%): 19.746639099021188
Capex to operating income (%): 22.05795162589884
Buffett classification: The Great
Stock price: 0.8251838020772552
P/E ratio: 7.037754482584434
Shares outstanding: 10320000
Book value: 8288742.108954873
P/B ratio: 1.02740521124876
Market cap (USD): 8515896.837437274
Debt to equity: 0.6562024430939087
Current ratio: 1.6212324685392343
Quick ratio: 1.6075243560523689
Effective tax rate (%): 24.07297374617636
Interest coverage ratio: 3.259371206302802
COGS to revenue (%): 10.485181435710663
SG&A to revenue (%): 0.39008716081791184
Free cash flow (dilution-adjusted): -3593207.855973813
Buyback yield (%): 0
Retained earnings: 3357809.212064531
Inventory turnover: 16.58052797287479
Receivables turnover: 1.7840424718020458
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 14.301088360241588
FCF margin (%): -23.53717314693283
Revenue growth (%): 60.374896367563366
Rule of 40 score: 36.83772322063054
Financial ratios for RELIABLE.NS — quarterly report dated 2025-03-31
Total revenue: 6196866.962824409
Gross profit: 5871101.239186346
Operating income: 232896.89034369885
Net income: 452747.2527472527
Capital expenditures: 0
Depreciation & amortization: 163701.19242459667
Net tangible assets: 6677589.43184475
Owner earnings: 616448.4451718493
Return on net tangible assets (%): 9.231601485291517
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.8251838020772552
P/E ratio: 4.702345947856747
Shares outstanding: 10320000
Book value: 8288742.108954873
P/B ratio: 1.02740521124876
Market cap (USD): 8515896.837437274
Debt to equity: 0.6562024430939087
Current ratio: 1.6212324685392343
Quick ratio: 1.6075243560523689
Effective tax rate (%): 18.758128802181666
Interest coverage ratio: 1.9439890710382515
COGS to revenue (%): 5.256942348324781
Buyback yield (%): 0
Retained earnings: 3357809.212064531
Inventory turnover: 3.374424800193752
Receivables turnover: 0.7241846638104397
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.1656325142730424
Revenue growth (%): 59.135166681844765
Rule of 40 score: 59.135166681844765
Financial ratios for RELIABLE.NS — quarterly report dated 2025-06-30
Total revenue: 4616709.571729464
Gross profit: 4029955.534753101
Operating income: 383664.8724549497
Net income: 196782.12029019426
Capital expenditures: 0
Depreciation & amortization: 115586.2391762228
Owner earnings: 312368.35946641705
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.8824011233325533
P/E ratio: 8.062866235019643
Shares outstanding: 10320000
Market cap (USD): 9106379.59279195
Effective tax rate (%): 26.00105605913931
Interest coverage ratio: 3.258596700457166
COGS to revenue (%): 12.709355610527599
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -25.499295056267275
Rule of 40 score: -25.499295056267275
Financial ratios for RELIABLE.NS — quarterly report dated 2025-09-30
Total revenue: 7793618.9402480265
Gross profit: 7478714.768883878
Operating income: 453742.9537767756
Net income: 252795.94137542276
Capital expenditures: 0
Depreciation & amortization: 192367.53100338217
Net tangible assets: 6814870.349492672
Owner earnings: 445163.47237880493
Return on net tangible assets (%): 6.532236851900562
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 1.3476888387824126
P/E ratio: 10.062195727048783
Shares outstanding: 10320000
Book value: 8437621.19503946
P/B ratio: 1.6483495163792374
Market cap (USD): 13908148.8162345
Debt to equity: 0.660611664352894
Current ratio: 1.991178542450113
Quick ratio: 1.9785598699320168
Effective tax rate (%): 25.999141942510146
Interest coverage ratio: 4.046551377438166
COGS to revenue (%): 4.040538468437452
Buyback yield (%): 0
Inventory turnover: 3.382417050133204
Receivables turnover: 0.7455868918797947
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.6384100093114076
Revenue growth (%): 68.8132818224574
Rule of 40 score: 68.8132818224574
Financial ratios for RELIABLE.NS — quarterly report dated 2025-12-31
Total revenue: 2613289.5176562327
Gross profit: 2212108.7222902975
Operating income: 570279.6034309904
Net income: 350384.31547287514
Capital expenditures: 0
Depreciation & amortization: 84738.77687423416
Owner earnings: 435123.0923471093
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 1.639968809179013
P/E ratio: 13.510296166774927
Shares outstanding: 10320000
Market cap (USD): 16924478.110727414
Effective tax rate (%): 26.001035147979106
Interest coverage ratio: 5.892495395948435
COGS to revenue (%): 15.351563332551846
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -66.46885692395597
Rule of 40 score: -66.46885692395597
Financial ratios for RIO.MC — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 3.465909090909091
Shares outstanding: 4818973
Market cap (USD): 16702122.329545455
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RIO.MC — annual report dated 2022-12-31
Total revenue: 19442553.19148936
Gross profit: 10801063.829787234
Operating income: 1332978.7234042555
Net income: 971276.595744681
Capital expenditures: 564893.6170212766
Operating cash flow: 2492553.1914893617
Depreciation & amortization: 1767021.2765957448
Net tangible assets: 22107446.80851064
Owner earnings: 2173404.2553191492
Return on net tangible assets (%): 9.831095712429624
Capex to operating income (%): 42.37829209896249
Buffett classification: The Good
Stock price: 4.25531914893617
P/E ratio: 21.112696604600217
Shares outstanding: 4818973
Book value: 22341489.36170213
P/B ratio: 0.917855911623256
Market cap (USD): 20506268.085106384
Debt to equity: 1.0117137279177182
Current ratio: 1.677666744132001
Quick ratio: 0.29556123634673487
Effective tax rate (%): 14.432989690721651
Interest coverage ratio: 6.053140096618358
COGS to revenue (%): 44.44626833005034
SG&A to revenue (%): 5.816371197198513
Free cash flow (dilution-adjusted): 1769148.936170213
Buyback yield (%): 0
Inventory turnover: 0.2731705676620931
Receivables turnover: 3.3174804864766747
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.9948987725171365
FCF margin (%): 9.09936528780915
Rule of 40 score: 9.09936528780915
Financial ratios for RIO.MC — annual report dated 2023-12-31
Total revenue: 19290000
Gross profit: 11318888.888888888
Operating income: 805555.5555555555
Net income: 161111.1111111111
Capital expenditures: 2371111.111111111
Operating cash flow: -434444.44444444444
Depreciation & amortization: 2063333.3333333333
Net tangible assets: 22750000
Owner earnings: -146666.6666666665
Return on net tangible assets (%): -0.644688644688644
Capex to operating income (%): 294.34482758620686
Buffett classification: The Gruesome
Stock price: 5.133333333333334
P/E ratio: 153.54245006896554
Shares outstanding: 4818973
Book value: 23024444.44444444
P/B ratio: 1.0743970302094394
Market cap (USD): 24737394.733333334
Debt to equity: 1.0559308947012838
Current ratio: 1.5217424826522745
Quick ratio: 0.24537393986121828
Effective tax rate (%): 41.05691056910569
Interest coverage ratio: 1.8401015228426396
COGS to revenue (%): 41.32250446402857
SG&A to revenue (%): 6.457001324808479
Free cash flow (dilution-adjusted): -3015555.5555555555
Buyback yield (%): 0
Inventory turnover: 0.21667824458606422
Receivables turnover: 2.986068111455108
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.37269276083257
FCF margin (%): -15.632740049536316
Revenue growth (%): -0.7846355876559398
Rule of 40 score: -16.417375637192258
Financial ratios for RIO.MC — annual report dated 2024-12-31
Total revenue: 16763541.666666668
Gross profit: 9086458.333333334
Operating income: -1232291.6666666667
Net income: -2353125
Capital expenditures: 273958.3333333334
Operating cash flow: -3064583.3333333335
Depreciation & amortization: 1862500
Net tangible assets: 19158333.333333336
Owner earnings: -764583.3333333334
Return on net tangible assets (%): -3.990865593736407
Buffett classification: The Gruesome
Stock price: 3.4375
Shares outstanding: 4818973
Book value: 19402083.333333336
P/B ratio: 0.8537856168796305
Market cap (USD): 16565219.6875
Debt to equity: 1.184580693654032
Current ratio: 2.456572908085206
Quick ratio: 0.5124161468753679
Interest coverage ratio: -1.1429951690821256
COGS to revenue (%): 45.79630895420369
SG&A to revenue (%): 12.079786242465667
Free cash flow (dilution-adjusted): -3480208.3333333335
Buyback yield (%): 0
Inventory turnover: 0.22306970549956115
Receivables turnover: 2.4379639448568398
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -2.9394955895142254
FCF margin (%): -20.760579133784876
Revenue growth (%): -13.097243822360458
Rule of 40 score: -33.857822956145334
Financial ratios for RIO.MC — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 19158333.333333336
Buffett classification: The Gruesome
Stock price: 3.4375
Shares outstanding: 4818973
Book value: 19402083.333333336
P/B ratio: 0.8537856168796305
Market cap (USD): 16565219.6875
Debt to equity: 1.184580693654032
Current ratio: 2.456572908085206
Quick ratio: 0.5124161468753679
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RUBFILA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 33054479.216435738
Buffett classification: The Gruesome
Stock price: 0.9542522694696608
Shares outstanding: 54267529
Book value: 33120437.171524126
P/B ratio: 1.5635334895664847
Market cap (USD): 51784912.70676063
Debt to equity: 0.004125368800180897
Current ratio: 5.680762168443099
Quick ratio: 4.297443658638053
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RUBFILA.NS — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.9109453316237324
Shares outstanding: 54267529
Market cap (USD): 49434752.201305516
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RUBFILA.NS — annual report dated 2025-03-31
Total revenue: 64345662.8477905
Gross profit: 17102162.730886135
Operating income: 3946329.202712181
Net income: 3441489.3617021274
Capital expenditures: 797311.199438859
Operating cash flow: 2968868.365676876
Depreciation & amortization: 1281938.2744914659
Net tangible assets: 34328407.762450315
Owner earnings: 3926116.4367547343
Return on net tangible assets (%): 11.43693137160083
Capex to operating income (%): 20.203869431138525
Buffett classification: The Great
Stock price: 0.7263391294200023
P/E ratio: 11.453363827961871
Shares outstanding: 54267529
Book value: 34372165.06897358
P/B ratio: 1.1467601674360222
Market cap (USD): 39416629.76963473
Debt to equity: 0.0037558733349318664
Current ratio: 5.185426683537186
Quick ratio: 4.102055391536623
Effective tax rate (%): 25.968444453385906
Interest coverage ratio: 273.7785888077859
COGS to revenue (%): 73.42142115881026
Free cash flow (dilution-adjusted): 2130640.635959785
Buyback yield (%): 0
Retained earnings: 25685620.762216505
Inventory turnover: 10.488446694921633
Receivables turnover: 8.254343027161916
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 10.454868820538518
FCF margin (%): 3.311242035068952
Revenue growth (%): 14.215306079436457
Rule of 40 score: 17.52654811450541
Financial ratios for RUBFILA.NS — quarterly report dated 2025-03-31
Total revenue: 17239689.034369886
Gross profit: 4691255.55295768
Operating income: 1149660.9773205516
Net income: 971370.1192424597
Capital expenditures: 0
Operating cash flow: -35.07131166705634
Depreciation & amortization: 321931.26022913255
Net tangible assets: 34328407.762450315
Owner earnings: 1293301.3794715921
Return on net tangible assets (%): 3.7674377105432
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.7263391294200023
P/E ratio: 10.144596016700229
Shares outstanding: 54267529
Book value: 34372153.37853636
P/B ratio: 1.1467605574647641
Market cap (USD): 39416629.76963473
Debt to equity: 0.0037558746123555107
Current ratio: 5.185426683537186
Quick ratio: 4.102055391536623
Effective tax rate (%): 26.403663386506764
Interest coverage ratio: 332.23648648648646
COGS to revenue (%): 72.7880500419412
Free cash flow (dilution-adjusted): -35.07131166705634
Buyback yield (%): 0
Inventory turnover: 2.7858557335693392
Receivables turnover: 2.2115291174776854
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.0457557108306714
FCF margin (%): -0.0002034335514819117
Rule of 40 score: -0.0002034335514819117
Financial ratios for RUBFILA.NS — quarterly report dated 2025-06-30
Total revenue: 16958834.542476013
Gross profit: 4449461.736484906
Operating income: 837772.0571027382
Net income: 782763.8661362041
Capital expenditures: 271015.67985022237
Operating cash flow: -1026328.1067165927
Depreciation & amortization: 315445.82260706765
Owner earnings: 827194.0088930496
Capex to operating income (%): 32.349572601821336
Buffett classification: The Good
Stock price: 0.9873625087760356
P/E ratio: 30.545969706498568
Shares outstanding: 54267529
Market cap (USD): 53581723.57851627
Effective tax rate (%): 25.06860823298796
Interest coverage ratio: 265.17037037037034
COGS to revenue (%): 73.76316323305977
Free cash flow (dilution-adjusted): -1304961.3854434823
Buyback yield (%): 0
Capitalized R&D asset: 0
FCF margin (%): -7.694876568168676
Revenue growth (%): -1.6291157649882628
Rule of 40 score: -9.323992333156939
Financial ratios for RUBFILA.NS — quarterly report dated 2025-09-30
Total revenue: 16937621.19503946
Gross profit: 4491623.449830891
Operating income: 924408.1172491544
Net income: 902006.7643742954
Capital expenditures: 258049.60541149942
Operating cash flow: 1577260.428410372
Depreciation & amortization: 305963.9233370913
Net tangible assets: 33538635.851183765
Owner earnings: 949921.0822998873
Return on net tangible assets (%): 2.832318781583239
Capex to operating income (%): 27.915116775413136
Buffett classification: The Good
Stock price: 0.9428410372040585
P/E ratio: 19.263155890221597
Shares outstanding: 54267529
Book value: 33580191.6572717
P/B ratio: 1.5236855659155102
Market cap (USD): 51165653.328861326
Debt to equity: 0.0035543985472189107
Current ratio: 5.380432470151731
Quick ratio: 4.147793256234168
Effective tax rate (%): 23.865712545676008
Interest coverage ratio: 146.41964285714286
COGS to revenue (%): 73.48137971614126
Free cash flow (dilution-adjusted): 1313348.3652762119
Buyback yield (%): 0
Inventory turnover: 2.540490534949119
Receivables turnover: 2.0848950035803697
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.503879723383815
FCF margin (%): 7.754030806054713
Revenue growth (%): -0.12508729525854287
Rule of 40 score: 7.62894351079617
Financial ratios for RUBFILA.NS — quarterly report dated 2025-12-31
Total revenue: 16345594.296535593
Gross profit: 4283758.49392893
Operating income: 647911.3289517657
Net income: 613033.3073409825
Capital expenditures: 307274.1450373176
Operating cash flow: 93227.13601425866
Depreciation & amortization: 313746.2403921132
Net tangible assets: 33728684.41572909
Owner earnings: 619505.4026957781
Return on net tangible assets (%): 1.8367315933819135
Capex to operating income (%): 47.42533913312587
Buffett classification: The Good
Stock price: 0.8330177119304891
P/E ratio: 13.827900273956704
Shares outstanding: 54267529
Book value: 33792970.92569901
P/B ratio: 1.3377282790286773
Market cap (USD): 45205812.839701466
Debt to equity: 0.0034150900169600757
Current ratio: 6.145371583967157
Quick ratio: 4.7718591782236786
Effective tax rate (%): 26.236495724204488
Interest coverage ratio: 218.6578947368421
COGS to revenue (%): 73.79258033562682
Free cash flow (dilution-adjusted): -285785.8972930823
Buyback yield (%): 0
Inventory turnover: 2.5767118332690817
Receivables turnover: 2.0571867591412594
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.7452273524472282
FCF margin (%): -1.748397103882934
Revenue growth (%): -3.495336751758586
Rule of 40 score: -5.24373385564152
Financial ratios for SGZ.V — annual report dated 2021-06-30
Total revenue: 0
Gross profit: -20249.1935483871
Operating income: -204601.61290322582
Net income: -200319.35483870967
Capital expenditures: 568448.3870967742
Operating cash flow: -79650.80645161291
Depreciation & amortization: 20249.1935483871
Net tangible assets: 4489953.225806451
Owner earnings: -748518.5483870967
Return on net tangible assets (%): -16.670965391909032
Buffett classification: The Gruesome
Stock price: 0.08870967741935484
Shares outstanding: 214016316
Book value: 4489953.225806451
P/B ratio: 4.228400030031207
Market cap (USD): 18985318.35483871
Debt to equity: 0.008540393588409393
Current ratio: 1.0571580671580671
Quick ratio: 1.0571580671580671
Interest coverage ratio: -40.49577015163608
Free cash flow (dilution-adjusted): -665211.2903225807
Buyback yield (%): 0
Retained earnings: -3331542.741935484
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4.538111002753927
Rule of 40 score: 0
Financial ratios for SGZ.V — annual report dated 2022-06-30
Total revenue: 0
Gross profit: -19987.596899224805
Operating income: -306231.00775193796
Net income: -261837.98449612403
Capital expenditures: 690874.4186046511
Operating cash flow: -316303.87596899224
Depreciation & amortization: 19987.596899224805
Net tangible assets: 4909805.426356589
Owner earnings: -932724.8062015504
Return on net tangible assets (%): -18.997184719266887
Buffett classification: The Gruesome
Stock price: 0.03875968992248062
Shares outstanding: 214016316
Book value: 4909805.4263565885
P/B ratio: 1.689518285588608
Market cap (USD): 8295206.046511628
Debt to equity: 0.0028372270076854594
Current ratio: 1.2315752292243622
Quick ratio: 1.2315752292243622
Free cash flow (dilution-adjusted): -1065837.984496124
Buyback yield (%): 0
Retained earnings: -3441150.387596899
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -6.237131233511677
Rule of 40 score: 0
Financial ratios for SGZ.V — annual report dated 2023-06-30
Total revenue: 0
Gross profit: -11875.93984962406
Operating income: -228460.90225563908
Net income: -224309.7744360902
Capital expenditures: 110903.75939849623
Operating cash flow: -109335.33834586466
Depreciation & amortization: 11875.93984962406
Net tangible assets: 4588151.127819548
Owner earnings: -323337.5939849624
Return on net tangible assets (%): -7.047230681318552
Buffett classification: The Gruesome
Stock price: 0.022556390977443608
Shares outstanding: 214016316
Book value: 4588151.127819548
P/B ratio: 1.0521527222540048
Market cap (USD): 4827435.69924812
Debt to equity: 0
Current ratio: 0.21298263844294738
Quick ratio: 0.21298263844294738
Free cash flow (dilution-adjusted): -270557.8947368421
Buyback yield (%): 0
Retained earnings: -3259245.864661654
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4.9793674160034
Rule of 40 score: 0
Financial ratios for SGZ.V — annual report dated 2024-06-30
Total revenue: 0
Gross profit: -586.1313868613138
Operating income: -160357.66423357662
Net income: -160357.66423357662
Capital expenditures: 47675.91240875912
Operating cash flow: -135409.4890510949
Depreciation & amortization: 586.1313868613138
Net tangible assets: 4513759.124087591
Owner earnings: -207447.44525547442
Return on net tangible assets (%): -4.59589090938493
Buffett classification: The Gruesome
Stock price: 0.0218978102189781
Shares outstanding: 214016316
Book value: 4513759.124087591
P/B ratio: 1.038267338308659
Market cap (USD): 4686488.671532846
Debt to equity: 0
Current ratio: 0.38860757203305496
Quick ratio: 0.38860757203305496
Free cash flow (dilution-adjusted): -139354.74452554743
Buyback yield (%): 0
Retained earnings: -3315866.423357664
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -3.552641153973657
Rule of 40 score: 0
Financial ratios for SGZ.V — quarterly report dated 2024-09-30
Capital expenditures: 20954.814814814814
Buffett classification: The Gruesome
Stock price: 0.02222222222222222
Shares outstanding: 214016316
Market cap (USD): 4755918.133333333
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0